此次延期议案已获公司第九届董事会第二十三次会议审议通过，无需提交股东会审议。公司保荐机构中 信证券对此表示无异议。 金陵药业（000919）1月20日晚间公告，公司拟将"核心原料药及高端医药中间体共性生产平台建设项 目"的达产日期由原定的2026年3月延期至2028年3月，延期24个月。值得注意的是，该项目拟投入募集 资金1亿元，截至2025年9月底实际仅使用256.99万元，投资进度不足3%。 根据公告，金陵药业于2024年3月完成向特定对象发行股票，募集资金总额7.5亿元，净额7.43亿元。其 中，原料药项目投资预算1.44亿元，计划使用募资1亿元。 然而，项目推进速度远低于预期。截至2025年9月30日，该项目累计投入仅256.99万元，投资进度为 2.57%。相比之下，拟投入募集资金6亿元的合肥金陵天颐智慧养老项目，仅投入37.48万元。此外，补 充流动资金项目已使用2435.05万元。 公司方面表示，延期决定是基于"严格把控项目整体质量"的考量，需妥善满足工艺流程、安全、环保等 方面的管理要求。此次调整不涉及项目实施主体、投资总额及募集资金用途的变更。 数据显示，截至2025年9月底，公司募集资金余 ...

Core Viewpoint - The operating situation of North Huajin Chemical Industry Co., Ltd. remains severe in the first half of 2025, with a continued decline in revenue and an expanded net loss compared to the previous year [1][2]. Group 1: Financial Performance - In the first half of 2025, the company reported an operating revenue of 20.104 billion yuan, a year-on-year decrease of 5.01% [1][2]. - The net loss attributable to shareholders reached 989 million yuan, with the loss scale increasing by 33.15% year-on-year [1][2]. - Following a peak revenue of 49.062 billion yuan in 2022, both revenue and net profit have been declining since 2023, with a significant loss of 2.795 billion yuan in 2024 [2]. Group 2: Business Operations - North Huajin primarily engages in the production and sale of chemical fertilizers and has expanded into petrochemical products, refining, and ethylene since 2007 [2]. - The company has established a comprehensive refining and chemical integration industry chain, including refining, polyolefins, ABS, and pseudocumene [2]. - The decline in performance is attributed to multiple factors, including insufficient global economic growth, fluctuating international oil prices, and increased domestic production capacity [2]. Group 3: Fund Utilization Issues - The company has approximately 3 billion yuan of raised funds that have remained uninvested since they were received at the end of 2014, indicating a long-term idle status [4][6]. - The funds were initially intended for a project in Inner Mongolia, which was halted due to economic feasibility concerns and lack of stable low-cost raw material supply [4][5]. - The prolonged idleness of these funds has raised concerns about corporate governance and the potential negative impact on shareholder value and company performance [6][7].